These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33466174)

  • 1. Lusutrombopag as a substitute for platelet transfusion for thrombocytopenia associated with chronic liver disease in a patient undergoing endoscopic spinal surgery: A case report.
    Kaneko T; Takano Y; Ishibashi K
    Medicine (Baltimore); 2021 Jan; 100(2):e24094. PubMed ID: 33466174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
    Armstrong N; Büyükkaramikli N; Penton H; Riemsma R; Wetzelaer P; Huertas Carrera V; Swift S; Drachen T; Raatz H; Ryder S; Shah D; Buksnys T; Worthy G; Duffy S; Al M; Kleijnen J
    Health Technol Assess; 2020 Oct; 24(51):1-220. PubMed ID: 33108266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).
    Peck-Radosavljevic M; Simon K; Iacobellis A; Hassanein T; Kayali Z; Tran A; Makara M; Ben Ari Z; Braun M; Mitrut P; Yang SS; Akdogan M; Pirisi M; Duggal A; Ochiai T; Motomiya T; Kano T; Nagata T; Afdhal N
    Hepatology; 2019 Oct; 70(4):1336-1348. PubMed ID: 30762895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
    Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
    J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
    Hidaka H; Kurosaki M; Tanaka H; Kudo M; Abiru S; Igura T; Ishikawa T; Seike M; Katsube T; Ochiai T; Kimura K; Fukuhara T; Kano T; Nagata T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1192-1200. PubMed ID: 30502505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures.
    Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Shimizu T; Watakabe K; Enomoto N; Izumi N
    PLoS One; 2019; 14(2):e0211122. PubMed ID: 30768601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between response to lusutrombopag and splenic volume.
    Uojima H; Arase Y; Itokawa N; Atsukawa M; Satoh T; Miyazaki K; Hidaka H; Sung JH; Kako M; Tsuruya K; Kagawa T; Iwakiri K; Horie R; Koizumi W
    World J Gastroenterol; 2018 Dec; 24(46):5271-5279. PubMed ID: 30581275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Repeated Lusutrombopag Administration for Thrombocytopenia in a Patient Scheduled for Invasive Hepatocellular Carcinoma Treatment.
    Sato S; Miyake T; Kataoka M; Isoda K; Yazaki T; Tobita H; Ishimura N; Kinoshita Y
    Intern Med; 2017 Nov; 56(21):2887-2890. PubMed ID: 28943563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
    Biolato M; Vitale F; Marrone G; Miele L; Grieco A
    Medicine (Baltimore); 2022 Nov; 101(44):e31429. PubMed ID: 36343065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure.
    Shirley M; McCafferty EH; Blair HA
    Drugs; 2019 Oct; 79(15):1689-1695. PubMed ID: 31529283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient.
    Sakamaki A; Watanabe T; Abe S; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Terai S
    Clin J Gastroenterol; 2017 Jun; 10(3):261-264. PubMed ID: 28324272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Lusutrombopag in Patients with Mild to Moderate Thrombocytopenia.
    Tsuji Y; Kawaratani H; Ishida K; Kaya D; Kubo T; Fujinaga Y; Sawada Y; Takaya H; Shimozato N; Kaji K; Namisaki T; Moriya K; Akahane T; Yoshiji H
    Dig Dis; 2020; 38(4):329-334. PubMed ID: 31655803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child-Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance.
    Flamm SL; Peck-Radosavljevic M; Fukuhara T; Bentley R; Katsube T; Ochiai T; Kano T; Tsukimura E; Sasaki R; Osaki Y
    Adv Ther; 2022 Sep; 39(9):4285-4298. PubMed ID: 35904722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lusutrombopag: First Global Approval.
    Kim ES
    Drugs; 2016 Jan; 76(1):155-8. PubMed ID: 26666417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Lusutrombopag on Post-invasive Procedural Bleeding in Thrombocytopenic Patients with Chronic Liver Disease.
    Yoshida M; Tateishi R; Hiroi S; Hongo Y; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Jan; 39(1):379-390. PubMed ID: 34748184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two cases of liver cirrhosis treated with lusutrombopag before partial splenic embolization.
    Fujita M; Abe K; Hayashi M; Okai K; Takahashi A; Ohira H
    Fukushima J Med Sci; 2017 Dec; 63(3):165-171. PubMed ID: 29142151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding events in lusutrombopag-treated thrombocytopenic patients.
    Giannini EG; Kano T; Ochiai T; Bentley R; Shrestha P; Afdhal N
    Eur J Clin Invest; 2021 Jun; 51(6):e13503. PubMed ID: 33523482
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.
    Tateishi R; Seike M; Kudo M; Tamai H; Kawazoe S; Katsube T; Ochiai T; Fukuhara T; Kano T; Tanaka K; Kurokawa M; Yamamoto K; Osaki Y; Izumi N; Imawari M
    J Gastroenterol; 2019 Feb; 54(2):171-181. PubMed ID: 30105510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/Pharmacodynamic Modelling and Simulation of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist, for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Katsube T; Shimizu R; Fukuhara T; Kano T; Wajima T
    Clin Pharmacokinet; 2019 Nov; 58(11):1469-1482. PubMed ID: 31055790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.